Interferon-beta therapy in multiple sclerosis: The short-term and long-term effects on the patients' individual gene expression in peripheral blood

Molecular Neurobiology

Volumn 48, Issue 3, 2013, Pages 737-756

  Hecker, Michael ^a,b   Hartmann, Christiane ^b   Kandulski, Ole ^b   Paap, Brigitte Katrin ^b   Koczan, Dirk ^b   Thiesen, Hans Juergen ^b   Zettl, Uwe Klaus ^b  

^a Steinbeis Transfer Center for Proteome Analysis   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Gene expression; Interferon beta; Multiple sclerosis; Network analysis; Peripheral blood

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BETA1A INTERFERON; CD163 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; GLATIRAMER; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; INTERFERON REGULATORY FACTOR 7; INTERFERON REGULATORY FACTOR 9; INTERFERON STIMULATED GENE FACTOR 3; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; RETINOIC ACID INDUCIBLE PROTEIN I; STAT1 PROTEIN; STAT2 PROTEIN;

ADAPTIVE IMMUNITY; ADULT; BLOOD SAMPLING; CELL MIGRATION; CLINICAL ARTICLE; DISEASE ACTIVITY; DNA BINDING MOTIF; DOWN REGULATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEEDBACK SYSTEM; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LONG TERM CARE; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; SHORT COURSE THERAPY; TISSUE MICROARRAY; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ADULT; BASE SEQUENCE; BINDING SITES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84887996143     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8463-1     Document Type: Review

References (147)

1. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502-1517
2. McFarland HF, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8(9):913-919
3. Zettl UK, Stüve O, Patejdl R (2012) Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 11(3):167-173. doi: 10.1016/j.autrev.2011.05.008
4. Kakalacheva K, Münz C, Lünemann JD (2011) Viral triggers of multiple sclerosis. Biochim Biophys Acta 1812(2):132-140
5. Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23:683-747
6. Vosoughi R, Freedman MS (2010) Therapy of MS. Clin Neurol Neurosurg 112(5):365-385
7. Mendes A, Sá MJ (2011) Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works. Arq Neuropsiquiatr 69(3):536-543
8. Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 255(10):1449-1463
9. Kieseier BC, Calabresi PA (2012) PEGylation of interferon-beta-1a: a promising strategy in multiple sclerosis. CNS Drugs 26(3):205-214. doi: 10.2165/11596970-000000000-00000
10. De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, Gasperini C (2012) Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study. J Neurol Sci 312(1-2):97-101
11. 3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 83(5):565-571
12. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6(12):975-990
13. Kadowaki N, Antonenko S, Lau JY, Liu YJ (2000) Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 192(2):219-226
14. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472(7344):481-485
15. Hundeshagen A, Hecker M, Paap BK, Angerstein C, Kandulski O, Fatum C, Hartmann C, Koczan D, Thiesen HJ, Zettl UK (2012) Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. J Neuroinflammation 9:140
16. Dhib-Jalbut S, Marks S (2010) Interferon-beta mechanisms of action in multiple sclerosis. Neurology 74(Suppl 1):S17-S24
17. Killestein J, Polman CH (2011) Determinants of interferon beta efficacy in patients with multiple sclerosis. Nat Rev Neurol 7(4):221-228
18. Sørensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J, Polman C, Pozzilli C, Ross C, EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis (2005) Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12(11):817-827
19. Capra R, Sottini A, Cordioli C, Serana F, Chiarini M, Caimi L, Padovani A, Bergamaschi R, Imberti L (2007) IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. J Neuroimmunol 189(1-2):102-110
20. Graber JJ, Dhib-Jalbut S (2011) Biomarkers of disease activity in multiple sclerosis. J Neurol Sci 305(1-2):1-10
21. Hecker M, Paap BK, Goertsches RH, Kandulski O, Fatum C, Koczan D, Hartung HP, Thiesen HJ, Zettl UK (2011) Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis. PLoS One 6(12):e29648
22. Kemppinen AK, Kaprio J, Palotie A, Saarela J (2011) Systematic review of genome-wide expression studies in multiple sclerosis. BMJ Open 1(1):e000053
23. Goertsches RH, Zettl UK, Hecker M (2011) Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy. Pharmacogenomics 12(3):423-432
24. Croze E (2010) Differential gene expression and translational approaches to identify biomarkers of interferon beta activity in multiple sclerosis. J Interferon Cytokine Res 30(10):743-749
25. Goertsches RH, Hecker M, Zettl UK (2008) Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks. J Neurol 255(Suppl 6):48-57
26. Paap BK, Hundeshagen A, Hecker M, Zettl UK (2012) An inventory of short term and long term changes in gene expression under interferon beta treatment of relapsing remitting MS patients. Curr Pharm Des 18(29):4475-4484
27. Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Di Sapio A, Capobianco M, Bertolotto A (2005) Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 158(1-2):195-203
28. Santos R, Weinstock-Guttman B, Tamaño-Blanco M, Badgett D, Zivadinov R, Justinger T, Munschauer F 3rd, Ramanathan M (2006) Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J Neuroimmunol 176(1-2):125-133
29. Hartung HP (2009) High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opin Pharmacother 10(2):291-309. doi: 10.1517/14656560802677882
30. Annibali V, Di Giovanni S, Cannoni S, Giugni E, Bomprezzi R, Mattei C, Elkahloun A, Coccia EM, Alfò M, Orzi F, Ristori G, Salvetti M (2007) Gene expression profiles reveal homeostatic dynamics during interferon-beta therapy in multiple sclerosis. Autoimmunity 40(1):16-22
31. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121-127
32. Ferrari F, Bortoluzzi S, Coppe A, Sirota A, Safran M, Shmoish M, Ferrari S, Lancet D, Danieli GA, Bicciato S (2007) Novel definition files for human GeneChips based on GeneAnnot. BMC Bioinforma 8:446
33. Hecker M, Goertsches RH, Engelmann R, Thiesen HJ, Guthke R (2009) Integrative modeling of transcriptional regulation in response to antirheumatic therapy. BMC Bioinforma 10:262
34. Yang IV, Chen E, Hasseman JP, Liang W, Frank BC, Wang S, Sharov V, Saeed AI, White J, Li J, Lee NH, Yeatman TJ, Quackenbush J (2002) Within the fold: assessing differential expression measures and reproducibility in microarray assays. Genome Biol 3(11):research0062
35. Goertsches RH, Hecker M, Koczan D, Serrano-Fernandez P, Moeller S, Thiesen HJ, Zettl UK (2010) Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics 11(2):147-161
36. Serrano-Fernández P, Möller S, Goertsches R, Fiedler H, Koczan D, Thiesen HJ, Zettl UK (2010) Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. Autoimmunity 43(2):172-178
37. Falcon S, Gentleman R (2007) Using GOstats to test gene lists for GO term association. Bioinformatics 23(2):257-258
38. Watkins NA, Gusnanto A, de Bono B, De S, Miranda-Saavedra D, Hardie DL, Angenent WG, Attwood AP, Ellis PD, Erber W, Foad NS, Garner SF, Isacke CM, Jolley J, Koch K, Macaulay IC, Morley SL, Rendon A, Rice KM, Taylor N, Thijssen-Timmer DC, Tijssen MR, van der Schoot CE, Wernisch L, Winzer T, Dudbridge F, Buckley CD, Langford CF, Teichmann S, Göttgens B, Ouwehand WH, Consortium Bloodomics (2009) A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood 113(19):e1-e9. doi: 10.1182/blood-2008- 06-162958
39. Dreszer TR, Karolchik D, Zweig AS, Hinrichs AS, Raney BJ, Kuhn RM, Meyer LR, Wong M, Sloan CA, Rosenbloom KR, Roe G, Rhead B, Pohl A, Malladi VS, Li CH, Learned K, Kirkup V, Hsu F, Harte RA, Guruvadoo L, Goldman M, Giardine BM, Fujita PA, Diekhans M, Cline MS, Clawson H, Barber GP, Haussler D, James Kent W (2012) The UCSC Genome Browser database: extensions and updates 2011. Nucleic Acids Res 40(Database issue):D918-D923
40. Robertson G, Bilenky M, Lin K, He A, Yuen W, Dagpinar M, Varhol R, Teague K, Griffith OL, Zhang X, Pan Y, Hassel M, Sleumer MC, Pan W, Pleasance ED, Chuang M, Hao H, Li YY, Robertson N, Fjell C, Li B, Montgomery SB, Astakhova T, Zhou J, Sander J, Siddiqui AS, Jones SJ (2006) cisRED: a database system for genome-scale computational discovery of regulatory elements. Nucleic Acids Res 34(Database issue):D68-D73
41. Pachkov M, Erb I, Molina N, van Nimwegen E (2007) SwissRegulon: a database of genome-wide annotations of regulatory sites. Nucleic Acids Res 35(Database issue):D127-D131
42. Wingender E (2008) The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation. Brief Bioinform 9(4):326-332
43. Mahony S, Benos PV (2007) STAMP: a web tool for exploring DNA-binding motif similarities. Nucleic Acids Res 35(Web Server issue):W253-W258
44. FANTOM Consortium, Suzuki H, Forrest AR, van Nimwegen E, Daub CO, Balwierz PJ, Irvine KM, Lassmann T, Ravasi T, Hasegawa Y, de Hoon MJ, Katayama S, Schroder K, Carninci P, Tomaru Y, Kanamori-Katayama M, Kubosaki A, Akalin A, Ando Y, Arner E, Asada M, Asahara H, Bailey T, Bajic VB, Bauer D, Beckhouse AG, Bertin N, Björkegren J, Brombacher F, Bulger E, Chalk AM et al (2009) The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet 41(5):553-562
45. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, Sirota-Madi A, Olender T, Golan Y, Stelzer G, Harel A, Lancet D (2010) GeneCards Version 3: the human gene integrator. Database (Oxford) 2010:baq020
46. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T (2011) Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27(3):431-432
47. Bader GD, Hogue CW (2003) An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinforma 4:2
48. Morris JH, Apeltsin L, Newman AM, Baumbach J, Wittkop T, Su G, Bader GD, Ferrin TE (2011) clusterMaker: a multi-algorithm clustering plugin for Cytoscape. BMC Bioinforma 12:436
49. Ramana CV, Chatterjee-Kishore M, Nguyen H, Stark GR (2000) Complex roles of Stat1 in regulating gene expression. Oncogene 19(21):2619-2627
50. Barkhof F (2002) The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 15(3):239-245
51. Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G (2010) Evidence for a two-stage disability progression in multiple sclerosis. Brain 133(Pt 7):1900-1913
52. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289-300
53. Hecker M, Goertsches RH, Fatum C, Koczan D, Thiesen HJ, Guthke R, Zettl UK (2012) Network analysis of transcriptional regulation in response to intramuscular interferon-beta-1a multiple sclerosis treatment. Pharmacogenomics J 12(2):134-146. doi: 10.1038/tpj.2010.77
54. Gilli F, Valentino P, Caldano M, Granieri L, Capobianco M, Malucchi S, Sala A, Marnetto F, Bertolotto A (2008) Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Neurology 71(24):1940-1947
55. Farrell RA, Marta M, Gaeguta AJ, Souslova V, Giovannoni G, Creeke PI (2012) Development of resistance to biologic therapies with reference to IFN-beta. Rheumatology (Oxford) 51(4):590-599
56. Giovannoni G, Munschauer FE 3rd, Deisenhammer F (2002) Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 73(5):465-469
57. Sominanda A, Lundkvist M, Fogdell-Hahn A, Hemmer B, Hartung HP, Hillert J, Menge T, Kieseier BC (2010) Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. Arch Neurol 67(9):1095-1101
58. Ohya K, Kajigaya S, Kitanaka A, Yoshida K, Miyazato A, Yamashita Y, Yamanaka T, Ikeda U, Shimada K, Ozawa K, Mano H (1999) Molecular cloning of a docking protein, BRDG1, that acts downstream of the Tec tyrosine kinase. Proc Natl Acad Sci U S A 96(21):11976-11981
59. Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, Rassenti L, Kipps T, Croce CM (2008) Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A 105(50):19643-19648
60. Laine J, Künstle G, Obata T, Sha M, Noguchi M (2000) The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 6(2):395-407
61. Su L, David M (1999) Inhibition of B cell receptor-mediated apoptosis by IFN. J Immunol 162(11):6317-6321
62. Badr G, Saad H, Waly H, Hassan K, Abdel-Tawab H, Alhazza IM, Ahmed EA (2010) Type I interferon (IFN-alpha/beta) rescues B-lymphocytes from apoptosis via PI3Kdelta/Akt, Rho-A, NFkappaB and Bcl-2/Bcl(XL). Cell Immunol 263(1):31-40
63. Mix E, Stefan K, Höppner J, Klauer T, Zettl UK, Strauss U, Meyer-Rienecker HJ, Rolfs A (2003) Lymphocyte subpopulations, oxidative burst and apoptosis in peripheral blood cells of patients with multiple sclerosis-effect of interferon-beta. Autoimmunity 36(5):291-305
64. Zanotti C, Chiarini M, Serana F, Capra R, Rottoli M, Rovaris M, Cavaletti G, Clerici R, Rezzonico M, Caimi L, Imberti L (2011) Opposite effects of interferon-beta on new B and T cell release from production sites in multiple sclerosis patients. J Neuroimmunol 240-241:147-150
65. Saraste M, Irjala H, Airas L (2007) Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 28(3):121-126
66. Martínez-Rodríguez JE, López-Botet M, Munteis E, Rio J, Roquer J, Montalban X, Comabella M (2011) Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin Immunol 141(3):348-356
67. Shi FD, Van Kaer L (2006) Reciprocal regulation between natural killer cells and autoreactive T cells. Nat Rev Immunol 6(10):751-760
68. Jiang W, Chai NR, Maric D, Bielekova B (2011) Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol 187(2):781-790
69. Packard BZ, Telford WG, Komoriya A, Henkart PA (2007) Granzyme B activity in target cells detects attack by cytotoxic lymphocytes. J Immunol 179(6):3812-3820
70. Braud VM, Allan DS, O'Callaghan CA, Söderström K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ (1998) HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391(6669):795-799
71. Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park IK, Liu S, McClory S, Marcucci G, Trotta R, Caligiuri MA (2010) CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 115(2):274-281
72. Kärre K (2002) NK cells, MHC class I molecules and the missing self. Scand J Immunol 55(3):221-228
73. Oliveira CC, van Veelen PA, Querido B, de Ru A, Sluijter M, Laban S, Drijfhout JW, van der Burg SH, Offringa R, van Hall T (2010) The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. J Exp Med 207(1):207-221
74. Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julià E, Fernández M, Nonell L, Camiña-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R (2009) A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 132(Pt 12):3353-3365
75. van Boxel-Dezaire AH, Zula JA, Xu Y, Ransohoff RM, Jacobberger JW, Stark GR (2010) Major differences in the responses of primary human leukocyte subsets to IFN-beta. J Immunol 185(10):5888-5899
76. Cepok S, Schreiber H, Hoffmann S, Zhou D, Neuhaus O, von Geldern G, Hochgesand S, Nessler S, Rothhammer V, Lang M, Hartung HP, Hemmer B (2009) Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol 66(10):1216-1223
77. O'Boyle G, Brain JG, Kirby JA, Ali S (2007) Chemokine-mediated inflammation: identification of a possible regulatory role for CCR2. Mol Immunol 44(8):1944-1953
78. Müller M, Carter S, Hofer MJ, Campbell IL (2010) Review: the chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity - a tale of conflict and conundrum. Neuropathol Appl Neurobiol 36(5):368-387
79. Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29(6):313-326
80. Szczuciński A, Losy J (2007) Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 115(3):137-146
81. Mahad D, Callahan MK, Williams KA, Ubogu EE, Kivisäkk P, Tucky B, Kidd G, Kingsbury GA, Chang A, Fox RJ, Mack M, Sniderman MB, Ravid R, Staugaitis SM, Stins MF, Ransohoff RM (2006) Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 129(Pt 1):212-223
82. Buttmann M, Merzyn C, Rieckmann P (2004) Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J Neuroimmunol 156(1-2):195-203
83. Buttmann M, Goebeler M, Toksoy A, Schmid S, Graf W, Berberich-Siebelt F, Rieckmann P (2005) Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J Neuroimmunol 168(1-2):175-182
84. Seo JY, Yaneva R, Cresswell P (2011) Viperin: a multifunctional, interferon-inducible protein that regulates virus replication. Cell Host Microbe 10(6):534-539
85. Liu SY, Sanchez DJ, Cheng G (2011) New developments in the induction and antiviral effectors of type I interferon. Curr Opin Immunol 23(1):57-64
86. Gao S, von der Malsburg A, Dick A, Faelber K, Schröder GF, Haller O, Kochs G, Daumke O (2011) Structure of myxovirus resistance protein a reveals intra- and intermolecular domain interactions required for the antiviral function. Immunity 35(4):514-525
87. von der Malsburg A, Abutbul-Ionita I, Haller O, Kochs G, Danino D (2011) Stalk domain of the dynamin-like MxA GTPase protein mediates membrane binding and liposome tubulation via the unstructured L4 loop. J Biol Chem 286(43):37858-37865. doi: 10.1074/jbc.M111.249037
88. Haller O, Kochs G (2011) Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 31(1):79-87
89. Itsui Y, Sakamoto N, Kakinuma S, Nakagawa M, Sekine-Osajima Y, Tasaka-Fujita M, Nishimura-Sakurai Y, Suda G, Karakama Y, Mishima K, Yamamoto M, Watanabe T, Ueyama M, Funaoka Y, Azuma S, Watanabe M (2009) Antiviral effects of the interferon-induced protein guanylate binding protein 1 and its interaction with the hepatitis C virus NS5B protein. Hepatology 50(6):1727-1737
90. Kim BH, Shenoy AR, Kumar P, Das R, Tiwari S, MacMicking JD (2011) A family of IFN-beta-inducible 65-kD GTPases protects against bacterial infection. Science 332(6030):717-721
91. Hovanessian AG (2007) On the discovery of interferon-inducible, double-stranded RNA activated enzymes: the 2′-5′oligoadenylate synthetases and the protein kinase PKR. Cytokine Growth Factor Rev 18(5-6):351-361
92. Silverman RH (2007) Viral encounters with 2′,5′- oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol 81(23):12720-12729
93. O'Brien M, Lonergan R, Costelloe L, O'Rourke K, Fletcher JM, Kinsella K, Sweeney C, Antonelli G, Mills KH, O'Farrelly C, Hutchinson M, Tubridy N (2010) OAS1: a multiple sclerosis susceptibility gene that influences disease severity. Neurology 75(5):411-418
94. Cagliani R, Fumagalli M, Guerini FR, Riva S, Galimberti D, Comi GP, Agliardi C, Scarpini E, Pozzoli U, Forni D, Caputo D, Asselta R, Biasin M, Paraboschi EM, Bresolin N, Clerici M, Sironi M (2012) Identification of a new susceptibility variant for multiple sclerosis in OAS1 by population genetics analysis. Hum Genet 131(1):87-97. doi: 10.1007/s00439-011-1053-2
95. Fensterl V, Sen GC (2011) The ISG56/IFIT1 gene family. J Interferon Cytokine Res 31(1):71-78
96. Pindel A, Sadler A (2011) The role of protein kinase R in the interferon response. J Interferon Cytokine Res 31(1):59-70. doi: 10.1089/jir.2010.0099
97. Toroney R, Bevilacqua PC (2009) PKR and the ribosome compete for mRNA. Nat Chem Biol 5(12):873-874. doi: 10.1038/nchembio.262
98. Xiao S, Li D, Zhu HQ, Song MG, Pan XR, Jia PM, Peng LL, Dou AX, Chen GQ, Chen SJ, Chen Z, Tong JH (2006) RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc Natl Acad Sci U S A 103(44):16448-16453
99. Hallen LC, Burki Y, Ebeling M, Broger C, Siegrist F, Oroszlan-Szovik K, Bohrmann B, Certa U, Foser S (2007) Antiproliferative activity of the human IFN-alpha-inducible protein IFI44. J Interferon Cytokine Res 27(8):675-680
100. Leaman DW, Chawla-Sarkar M, Vyas K, Reheman M, Tamai K, Toji S, Borden EC (2002) Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem 277(32):28504-28511
101. Hebb AL, Moore CS, Bhan V, Robertson GS (2008) Targeting apoptosis to treat multiple sclerosis. Curr Drug Discov Technol 5(1):75-77
102. Sharief MK, Semra YK (2001) Upregulation of the inhibitor of apoptosis proteins in activated T lymphocytes from patients with multiple sclerosis. J Neuroimmunol 119(2):350-357
103. Sharief MK, Noori MA, Zoukos Y (2002) Reduced expression of the inhibitor of apoptosis proteins in T cells from patients with multiple sclerosis following interferon-beta therapy. J Neuroimmunol 129(1-2):224-231
104. Kirk S, Frank JA, Karlik S (2004) Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon? J Neurol Sci 217(2):125-130
105. Holley JE, Newcombe J, Whatmore JL, Gutowski NJ (2010) Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter. Neurosci Lett 470(1):65-70. doi: 10.1016/j.neulet.2009.12.059
106. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G (1995) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182(1):155-162
107. Feldman ED, Weinreich DM, Carroll NM, Burness ML, Feldman AL, Turner E, Xu H, Alexander HR Jr (2006) Interferon gamma-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann Surg Oncol 13(1):125-133
108. Mittelstadt ML, Patel RC (2012) AP-1 mediated transcriptional repression of matrix metalloproteinase-9 by recruitment of histone deacetylase 1 in response to interferon beta. PLoS One 7(8):e42152. doi: 10.1371/journal.pone. 0042152
109. Bernal F, Elias B, Hartung HP, Kieseier BC (2009) Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Mult Scler 15(6):721-727. doi: 10.1177/1352458509102920
110. Baggiolini M, Clark-Lewis I (1992) Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 307(1):97-101
111. Lund BT, Ashikian N, Ta HQ, Chakryan Y, Manoukian K, Groshen S, Gilmore W, Cheema GS, Stohl W, Burnett ME, Ko D, Kachuck NJ, Weiner LP (2004) Increased CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol 155(1-2):161-171
112. Li A, Dubey S, Varney ML, Dave BJ, Singh RK (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170(6):3369-3376
113. Stamenkovic I (2003) Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200(4):448-464
114. Osman M, Tortorella M, Londei M, Quaratino S (2002) Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases define the migratory characteristics of human monocyte-derived dendritic cells. Immunology 105(1):73-82
115. Yen JH, Kong W, Ganea D (2010) IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9. J Immunol 184(7):3478-3486. doi: 10.4049/jimmunol.0902542
116. Stüve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, Yong VW (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40(6):853-863
117. Descamps FJ, Van den Steen PE, Nelissen I, Van Damme J, Opdenakker G (2003) Remnant epitopes generate autoimmunity: from rheumatoid arthritis and multiple sclerosis to diabetes. Adv Exp Med Biol 535:69-77
118. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G (2000) Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 96(8):2673-2681
119. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson PB, Stabler G, Miller K (1999) Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53(7):1397-1401
120. Alexander JS, Harris MK, Wells SR, Mills G, Chalamidas K, Ganta VC, McGee J, Jennings MH, Gonzalez-Toledo E, Minagar A (2010) Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler 16(7):801-809. doi: 10.1177/1352458510370791
121. Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P, Livrea P, Trojano M (2003) Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 136(1-2):46-53
122. Benesová Y, Vasku A, Novotná H, Litzman J, Stourac P, Beránek M, Kadanka Z, Bednarík J (2009) Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler 15(3):316-322. doi: 10.1177/1352458508099482
123. Dunkelberger JR, Song WC (2010) Complement and its role in innate and adaptive immune responses. Cell Res 20(1):34-50. doi: 10.1038/cr.2009.139
124. Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11(9):785-797. doi: 10.1038/ni.1923
125. Davis AE 3rd, Lu F, Mejia P (2010) C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost 104(5):886-893. doi: 10.1160/TH10-01-0073
126. Cai S, Dole VS, Bergmeier W, Scafidi J, Feng H, Wagner DD, Davis AE III (2005) A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol 174(10):6462-6466
127. Engelhardt B, Ransohoff RM (2012) Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 33(12):579-589. doi: 10.1016/j.it.2012.07.004
128. Paun A, Pitha PM (2007) The IRF family, revisited. Biochimie 89(6-7):744-753
129. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N (2001) IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19:623-655
130. Kuo TC, Calame KL (2004) B lymphocyte-induced maturation protein (Blimp)-1, IFN regulatory factor (IRF)-1, and IRF-2 can bind to the same regulatory sites. J Immunol 173(9):5556-5563
131. Martins G, Calame K (2008) Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol 26:133-169. doi: 10.1146/annurev.immunol.26. 021607.090241
132. Nutt SL, Fairfax KA, Kallies A (2007) BLIMP1 guides the fate of effector B and T cells. Nat Rev Immunol 7(12):923-927
133. Doody GM, Stephenson S, McManamy C, Tooze RM (2007) PRDM1/BLIMP-1 modulates IFN-gamma-dependent control of the MHC class I antigen-processing and peptide-loading pathway. J Immunol 179(11):7614-7623
134. Boyer LA, Latek RR, Peterson CL (2004) The SANT domain: a unique histone-tail-binding module? Nat Rev Mol Cell Biol 5(2):158-163
135. Veals SA, Schindler C, Leonard D, Fu XY, Aebersold R, Darnell JE Jr, Levy DE (1992) Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. Mol Cell Biol 12(8):3315-3324
136. Schmidt A, Rothenfusser S, Hopfner KP (2012) Sensing of viral nucleic acids by RIG-I: from translocation to translation. Eur J Cell Biol 91(1):78-85
137. Loo YM, Gale M Jr (2011) Immune signaling by RIG-I-like receptors. Immunity 34(5):680-692
138. Sato M, Hata N, Asagiri M, Nakaya T, Taniguchi T, Tanaka N (1998) Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett 441(1):106-110
139. Panne D, Maniatis T, Harrison SC (2007) An atomic model of the interferon-beta enhanceosome. Cell 129(6):1111-1123
140. Tomura K, Narumi S (1999) Differential induction of interferon (IFN)-inducible protein 10 following differentiation of a monocyte, macrophage
141. Zhang D, Zhang DE (2011) Interferon-stimulated gene 15 and the protein ISGylation system. J Interferon Cytokine Res 31(1):119-130
142. Wong JJ, Pung YF, Sze NS, Chin KC (2006) HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc Natl Acad Sci U S A 103(28):10735-10740
143. Zhao C, Denison C, Huibregtse JM, Gygi S, Krug RM (2005) Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci U S A 102(29):10200-10205
144. Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10(1):57-63. doi: 10.1038/nrg2484
145. Waschbisch A, Atiya M, Linker RA, Potapov S, Schwab S, Derfuss T (2011) Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS One 6(9):e24604. doi: 10.1371/journal.pone.0024604
146. Angerstein C, Hecker M, Paap BK, Koczan D, Thamilarasan M, Thiesen HJ, Zettl UK (2012) Integration of MicroRNA databases to study MicroRNAs associated with multiple sclerosis. Mol Neurobiol 45(3):520-535. doi: 10.1007/s12035-012- 8270-0
147. Kraft S, Kinet JP (2007) New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 7(5):365-378